BioSpace News Archive

XOMA Corporation, the biotech royalty aggregator, announced that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in New York, NY.

Gain Therapeutics, Inc., a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, reports financial results for the quarter ended March 31, 2024, and provides a corporate update.

Profound Medical Corp. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the Company’s second TULSA-AI module, Contouring Assistant, for use in conjunction with its TULSA-PRO® system.

Alimera Sciences, Inc. today announced financial results for the first quarter of 2024.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency.

aTyr Pharma, Inc. announced that an independent data and safety monitoring board recommended that the ongoing Phase 3 EFZO-FIT™ study of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis could continue without any modifications after a second pre-planned, interim analysis.

Apellis Pharmaceuticals, Inc., announced that it has entered into a non-dilutive, senior secured credit facility with Sixth Street, a leading global investment firm, of up to $475 million, with approximately $375 million funded at close.

Halia Therapeutics today announced the unveiling of a new clinical program evaluating its candidate HT-4253 for the treatment of Alzheimer’s disease.

CASI Pharmaceuticals, Inc. today reported financial results for the three months ended March 31, 2024.

Scholar Rock today announced it will host an Investor Day on Wednesday, May 22, 2024 beginning at 8:30 a.m. ET in New York City.